<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165993</url>
  </required_header>
  <id_info>
    <org_study_id>KN026-201</org_study_id>
    <nct_id>NCT04165993</nct_id>
  </id_info>
  <brief_title>Study of KN026 Monotherapy or Combined With Chemotherapy in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Efficacy and Safety Evaluation of KN026 Monotherapy or Combined With Chemotherapy in Patients With HER2 Expressing or Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two-cohort phase 2 study of KN026 in subjects with advanced breast
      Cancer. The HER2 positive mBC subjects without systemic treatment will be enrolled in cohort
      1 and received 30 mg/kg KN026 and docetaxol. The HER2 expressing mBC subjects failed standard
      therapy will be enrolled in cohort 2 and received KN026 monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest</measure>
    <time_frame>From screening to up to 196 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-KN026 antibody</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Concurrent chemotherapy and KN026</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 combined with docetaxol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KN026 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026 combination</intervention_name>
    <description>30 mg/kg Q3W KN026 75 mg/m2 docetaxol</description>
    <arm_group_label>Concurrent chemotherapy and KN026</arm_group_label>
    <other_name>docetaxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026 monotherapy</intervention_name>
    <description>30 mg/kg Q3W KN026</description>
    <arm_group_label>KN026 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject &gt;= 18 years

          -  Histologically/cytologically confirmed, locally advanced unresectable or metastatic
             breast cancer

          -  ECOG score 0 or 1

          -  Life expectancy &gt;3 months

          -  According to the definition of RECIST1.1, the patient has at least one measurable
             lesion

          -  Adequate organ function prior to start treatment with KN026

          -  Able to understand, voluntarily participate and willing to sign the ICF

        Exclusion Criteria:

          -  Accepted any other anti-tumor drug therapies within 4 weeks before fist dose

          -  Accepted radiotherapy within 4 weeks before enrollment

          -  Subjects are eligible with clinically controlled and stable neurologic function &gt;= 4
             weeks, which is no evidence of CNS disease progression; Subjects with spinal cord
             compression and cancerous meningitis are not eligible

          -  Pregnant or nursing femalesï¼›or intend pregnancy within this study period or within 6
             monthes after the end of this study

          -  History of immunodeficiency, including HIV positive or other acquired, congenital
             immunodeficiency disease, or a history of organ transplantation

          -  History of immunodeficiency, including HIV positive or other acquired, congenital
             immunodeficiency disease, or a history of organ transplantation

          -  Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well
             controlled, and need locally treatment or repeated drainage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenhui Zhao, MD</last_name>
    <phone>045186298295</phone>
    <phone_ext>045186298295</phone_ext>
    <email>zhaowenhui1977@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhui Zhao, MD</last_name>
      <phone>8618745177632</phone>
      <email>zhaowenhui1977@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

